Related Experiment Video
Updated: Mar 30, 2026
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases
Wenbin Liu1, Dijiong Wu1, Tonglin Hu1
1Department of Hematology, First Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou, China.
Objective:
The purpose of our study was to evaluate the efficacy and safety of rituximab in treatment of immune PR.
Methods:
We retrospective analysis 7 paitents (5 aplastic anemia, 2 myelodysplastic syndrome) with immune PR who received at least 3 weekly infusions of rituximab (375 mg/m(2)).
Results:
All enrolled patients acquired improvement of platelets transfusion more than 2 months (CCI ≥ 4.5 × 10(9)/L). We first found that there were 2 patterns of response to rituximab treatment in patients with immune PR, which the early but transient after the first rituximab administration and the late but continuous beginning to appear at 3 weeks from the start of treatment.
Conclusion:
Rituximab is a promising treatment in patients with immune PR and giving the opportunity and time for cure the disease.
